To predict patients who respond to alvocidib, a biomarker-driven phase II study comparing FLAM vs. cytarabine and mitoxantrone in patients with MCL-1-dependent R/R AML is ongoing (NCT02520011). Here, MCL1 is linked to acute myeloid leukemia.